Antimicrobial Resistance in Rhodococcus equi

Area of Science:

• Veterinary Medicine
• Microbiology
• Antimicrobial Resistance

Background:

• Pneumonia caused by Rhodococcus equi is a significant cause of morbidity and mortality in foals.
• Macrolide and rifampin combination therapy has been the standard treatment since the 1980s, with historically low resistance rates.
• Recent increases in resistance to these drugs in Rhodococcus equi isolates are threatening treatment efficacy.

Purpose of the Study:

• To review current data on antimicrobial resistance in Rhodococcus equi.
• To emphasize the molecular mechanisms driving the emergence of macrolide and rifampin resistance in equine isolates.
• To provide insights into the evolving challenges of treating Rhodococcus equi infections in foals.

Main Methods:

• Literature review of studies on Rhodococcus equi antimicrobial resistance.
• Analysis of reported cases and resistance trends in equine isolates.
• Examination of molecular mechanisms underlying resistance development.

Main Results:

• Resistance to macrolides and rifampin in Rhodococcus equi isolates is significantly increasing.
• Some farms report up to 40% of infected foals have isolates resistant to both drug classes.
• Emergence of resistance is linked to specific molecular mechanisms.

Conclusions:

• The rising antimicrobial resistance in Rhodococcus equi poses a critical threat to foal health.
• Understanding the molecular basis of resistance is crucial for developing alternative treatment strategies.
• Continued surveillance and research are necessary to combat Rhodococcus equi infections effectively.